Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

Journal of Clinical Oncology

Volumn 12, Issue 10, 1994, Pages 2022-2034

  Ihde, Daniel C ^a   Mulshine, James L ^b   Kramer, Barnett S ^b   Steinberg, Seth M ^b   Linnoila, R Ilona ^b   Gazdar, Adi F ^b   Edison, Margaret ^b   Phelps, Ruby M ^b   Lesar, May ^b   Phares, John C ^b   Grayson, Jane ^b   Minna, John D ^b   Johnson, Bruce E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DROPERIDOL; ETOPOSIDE; LOMUSTINE; METHOTREXATE; METOCLOPRAMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG FEVER; DRUG MEGADOSE; FEMALE; HEARING LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 0028149937     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.10.2022     Document Type: Article

References (68)

1. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-591, 1980
2. Ihde DC: Drug therapy: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Cohen MH, Creaven PJ, Fossieck BE, et al: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349-354, 1977
4. Mehta C, Vogl SE: High-dose cyclophosphamide in the induction therapy of small cell lung cancer: Minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res 23:155, 1982 (abstr)
5. Schabel FM, Trader MW, Laster WR, et al: Cisdichlorodia-mineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459-1473, 1979
6. Evans WK, Feld R, Osoba D, et al: VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 53:1461-1466, 1984
7. Porter LL, Johnson DH, Hainsworth JD, et al: Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69:479-481, 1985
8. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 6:451-456, 1988
9. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 107:451-458, 1987
10. Woods RL, Levi J: Chemotherapy for small cell lung cancer: A randomized study of maintenance chemotherapy with cyclophosphamide, Adriamycin, and vincristine after remission induction with cis-platinum, VP-16-213, and radiotherapy. Proc Am Soc Clin Oncol 3:214, 1984 (abstr)
11. Bunn PA, Lichter AS, Makuch RW, et al: Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: A prospective randomized trial. Ann Intern Med 106:655-662, 1987
12. Ihde DC, Deisseroth AB, Lichter AS, et al: Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small cell lung cancer. J Clin Oncol 4:1443-1454, 1986
13. Zubrod CG, Schneiderman M, Frei E III, et al: Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene phosphoramide. J Chron Dis 11:7-33, 1960
14. Gazdar AF, Steinberg SM, Russell EK, et al: Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive stage small cell lung cancer: A prospective clinical trial. J Natl Cancer Inst 82:117-124, 1990
15. Ozols RF, Ihde DC, Linehan WM, et al: A randomized trial of standard chemotherapy versus a high dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6:1031-1040, 1988
16. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1287, 1984
17. Longo DL, De Vita VT, Duffey PL, et al: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991
18. Appendix A: Grading of Toxicity, in Wittes RE (ed): Manual of Oncologic Therapeutics 1991/1992. Philadelphia, PA, Lippincott, 1991, pp 445-448
19. Dearing MP, Steinberg SM, Phelps R, et al: Outcome of patients with small cell lung cancer: Effects of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 8:1042-1049, 1990
20. Radice PA, Matthews MJ, Ihde DC, et al: The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer 50:2894-2902, 1982
21. Stevenson HC, Gazdar AF, Linnoila RI, et al: Lack of relationship between in vitro tumor growth and prognosis in extensivestage small-cell lung cancer. J Clin Oncol 7:923-931, 1989
22. Morstyn G, Ihde DC, Lichter AS, et al: Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515-539, 1984
23. Simon RM: Design and conduct of clinical trials, in De Vita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 396-420
24. Rubinstein LV, Gail MH, Santner TJ: Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chron Dis 34:469-479, 1981
25. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 78:427-434, 1983
26. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
29. Harrell F: The PHGLM procedure, in SUGI Supplemental Library User's Guide. Cary, NC, SAS Institute, 1983, pp 267-294
30. Matthews DE, Farewell VT: Using and Understanding Medical Statistics. Basel, Switzerland, Karger, 1985, pp 148-158
31. Ihde DC, Makuch RW, Camey DN, et al: Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 123:500-507, 1981
32. Tannock IM, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
33. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
34. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
35. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
36. DeVita VT, Hubbard SM, Longo DL: The chemotherapy of lymphomas: Looking back, moving forward. Cancer Res 47:5810-5824, 1987
37. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9:499-508, 1991
38. Klasa R, Murray N, Coldman A: Dose intensity analysis of chemotherapy in small cell carcinoma of the lung. Proc Am Soc Clin Oncol 6:173, 1987 (abstr)
39. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990
40. Østerlind K, Andersen PK: Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46:4189-4194, 1986
41. Spiegelman D, Maurer LH, Ware JH, et al: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 7:344-354, 1989
42. Ruckdeschel J, Finkelstein D, Ettinger D, et al: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4:14-22, 1986
43. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
44. Meyer RM, Hryniuk WM, Goodyear MDE: The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9:339-347, 1991
45. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
46. Figueredo AT, Hryniuk WM, Strautmanis I, et al: Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 3:54-64, 1985
47. O'Donnell MR, Ruckdeschel JC, Baxter D, et al: Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep 69:571-575, 1985
48. Arriagada R, LeChevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993
49. Cavalli F, Sonntag RW, Jungi F, et al: VP-16-213 monotherapy for remission induction of small cell lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 62:473-475, 1978
50. Ihde DC, Pass HI, Glatstein EJ. Cancer of the lung: Section 2. Small cell lung cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 723-758
51. Wolff SN, Birch R, Sarma P, et al: Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:583-587, 1986
52. Klastersky J, Sculier J, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 4:1780-1786, 1986
53. Davis S, Rambotti P, Park YK: Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 65:955-958, 1981
54. Gralla RJ, Casper ES, Kelsen DP, et al: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95:414-420, 1981
55. Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
56. Scher H, Casper E, Gralla R, et al: Intensive induction chemotherapy with cisplatin + etoposide with radiotherapy for small cell lung cancer. Proceedings of the IV World Congress on Lung Cancer, Toronto, Canada, August 25-30, 1985, p 95
57. Brower M, Ihde DC, Johnston-Early A, et al: Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy. Am J Med 75:993-1000, 1983
58. Abeloff MD, Ettinger DS, Order SE, et al: Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat Rep 65:639-646, 1981
59. Johnson DH, Wolff SN, Hainsworth JD, et al: Extensivestage small-cell bronchogenic carcinoma: Intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 3:170-175, 1985
60. Johnson DH, DeLeo MJ, Hande KR, et al: High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol 5:703-709, 1987
61. Valdivieso M, Cabanillas F, Keating M, et al: Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. Am J Med 76:405-412, 1984
62. Masuda N, Fukuoka M, Matsui K, et al: Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65:2635-2640, 1990
63. Johnson DH, Hande KR, Hainsworth JD, et al: High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 67:957-958, 1983
64. Luikart SD, Propert KJ, Modeas CR, et al: High-dose etoposide therapy for extensive small cell lung cancer: A Cancer and Leukemia Group B study. Cancer Treat Rep 71:533-534, 1987
65. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
66. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
67. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
68. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992